Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer.

BACKGROUND Positron emission tomography (PET) scans often help direct biopsies of mediastinal lymph nodes in patients with non-small cell lung cancer (NSCLC), but the maximum standard uptake value (maxSUV) of individual nodes has not been evaluated. METHODS This is a prospective study of consecutive patients with NSCLC, all of whom underwent integrated fluorodeoxyglucose-positron emission-computed tomography (FDG-PET-CT) and had biopsy or resection of their mediastinal lymph nodes. RESULTS There were 397 patients. One-hundred and forty-three patients had N2 disease and 1,252 N2 nodes were pathologically examined. The median maxSUV of the nodes that had metastatic disease were the following: for the 2R node, 10.4 (range, 0-18.6); for 4R, 8.6 (range, 0-18.3); for 5, 8.9 (range, 0-26.3); for 6, 7.6 (range, 0-19.6); for 7, 7.7 (range, 0-14); for 8 and 9, 5.4 (range, 0-8.9). The median maxSUV for all of the N2 nodes that were benign was 0 (range, 0-18.8) (p < 0.05 for all stations except for nodes 8 and 9). When a maxSUV of 5.3 is used the accuracy of integrated FDG-PET-CT for each N2 nodal station is maximized and is at least 92% for each. CONCLUSIONS The maxSUV of individual mediastinal lymph nodes is a predictor of malignancy. There is overlap between false and true positives. Definitive biopsies are required to prove cancer irrespective of the maxSUV value. However, when a maxSUV of 5.3 is used instead of the traditional value of 2.5, the accuracy for FDG-PET-CT for each N2 nodal station increases to at least 92%.

[1]  R. Cerfolio,et al.  Distribution and likelihood of lymph node metastasis based on the lobar location of nonsmall-cell lung cancer. , 2006, The Annals of thoracic surgery.

[2]  S. Larson,et al.  Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  H. Schäfers,et al.  Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. , 2003, The Annals of thoracic surgery.

[4]  G. Grunkemeier,et al.  Receiver operating characteristic curve analysis of clinical risk models. , 2001, The Annals of thoracic surgery.

[5]  Alfred A Bartolucci,et al.  The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. , 2004, The Annals of thoracic surgery.

[6]  R. Cerfolio,et al.  The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. , 2005, The Journal of thoracic and cardiovascular surgery.

[7]  J. Zubeldia,et al.  Clinical applications of (18)F-FDG in oncology. , 2002, Journal of nuclear medicine technology.

[8]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[9]  Improved Radiologic Staging of Lung Cancer with 2-[18F]-Fluoro-2-Deoxy-d-Glucose–Positron Emission Tomography and Computed Tomography Registration , 2003, Journal of computer assisted tomography.

[10]  R. Cerfolio,et al.  Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial. , 2005, The Annals of thoracic surgery.

[11]  Thomas Beyer,et al.  Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. , 2003, Radiology.

[12]  J. R. Beck,et al.  Likelihood ratios. Another enhancement of sensitivity and specificity. , 1986, Archives of pathology & laboratory medicine.

[13]  G. Gladish,et al.  Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. , 2004, AJR. American journal of roentgenology.

[14]  Thanos Athanasiou,et al.  Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. , 2005, The Annals of thoracic surgery.

[15]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[16]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[17]  J. Mountz,et al.  The role of FDG-PET scan in staging patients with nonsmall cell carcinoma. , 2003, The Annals of thoracic surgery.